Drug search by name

Leukine (Sargramostim Powder for Injection) and Leukocytosis

Result of checking the interaction of drug Leukine (Sargramostim Powder for Injection) and disease Leukocytosis for safety when used together.

Check result:

Leukine (Sargramostim Powder for Injection) <> Leukocytosis

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Sargramostim is a growth factor for hematopoietic progenitor cells. Therefore, it should not be used in patients with leukocytosis. During sargramostim treatment, if the absolute neutrophil count (ANC) exceeds 20,000 cells/mm3 or white blood cell count (WBC) exceeds 50,000 cells/mm3, therapy should be interrupted or the dosage reduced by half, depending on the clinical condition of the patient. Blood counts generally return to normal or baseline levels within 3 to 7 days of stopping therapy.

References:

"Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA.
"Product Information. Prokine (sargramostim)." Hoechst Marion-Roussel Inc, Kansas City, MO.

Leukine (Sargramostim Powder for Injection)

Generic Name: sargramostim

Brand Name: Leukine

Synonyms: Leukine

What is Leukine (Sargramostim Powder for Injection)?